Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications. We show 21 historical shares outstanding datapoints in our APLS shares outstanding history coverage, used to compute APLS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APLS market cap history over the course of time is important for investors
interested in comparing APLS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APLS versus a peer is one thing; comparing
APLS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APLS can fluctuate over the course of history.
With this page we aim to empower investors researching APLS by allowing them to research the APLS market cap history. |
Free APLS Email Alerts:
Video: The Importance of Market Cap
